You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 貝達藥業大升超13% 注射用MCLA-129獲臨牀試驗批准
格隆匯 11-20 10:11
貝達藥業(300558.SZ)大幅拉昇升超13%,現報53.2元,總市值222億元。公司昨日盤後公吿,公司申報的注射用MCLA-129擬用於“晚期實體瘤”的藥物臨牀試驗申請已獲得國家藥品監督管理局批准。MCLA-129是一款針對表皮生長因子受體和細胞間質上皮轉化因子雙靶點的雙特異性抗體,可同時阻斷EGFR和c-Met的信號傳導,抑制腫瘤的生長和存活,並且可經增強的抗體依賴的細胞介導的細胞毒性作用進一步提高對腫瘤細胞的殺傷潛能。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account